PRO-1106

N/A

Report date: 2024/04/23 16:51:04

Base Information

Drug NamePRO-1106

Drug Alias NamePRO-1106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-SLITRK6

TargetsDNA topoisomerase ISLIT and NTRK-like protein 6

Therapy Area/IndicationsCarcinoma, Transitional Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesProfoundBio (Suzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesProfoundBio (Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Transitional Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A